If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFFWD.L Regulatory News (FFWD)

  • There is currently no data for FFWD

Director/PDMR Shareholding

25 May 2016 11:45

RNS Number : 2836Z
FastForward Innovations Limited
25 May 2016
 

For immediate release

25 May 2016

FastForward Innovations Limited

("FastForward" or the "Company")

Director Dealing

FastForward Innovations Limited (AIM: FFWD) announces that:

· Mr Bryan Smith, a director of the Company, has purchased 467,836 ordinary shares from Mr Lorne Abony (a director of the Company) at a price of £0.15 per share, for total consideration of £70,175.40; and

· Mr Abony has sold a further 1,473,685 shares to Ms Wendy Polland at a price of £0.15 per share, for total consideration of £221,052.75.

Each of the sales was completed on 25 May 2016.

Commenting on the disposals Mr Abony noted:

"It is important that shareholders do not perceive this as me reducing my interest in the Company. Mr Smith has been looking to purchase a US$100,000 block of shares for some time and was unable to participate in the February 2016 placing as he was one of the independent directors for the purposes of the transaction. Now, with the publication of the accounts to 31 March 2016 yesterday, the Company is out of the recent close period, I am happy to assist him with his purchase.

With regards my sale of a further 1,473,685 shares to Ms Polland, Ms Polland is my ex-wife. She was a significant investor in the placing of the Company announced on 22 December 2015, but due to circumstances beyond her control could not participate in the February 2016 placing at £0.15. I am honouring a personal commitment to her by transferring these shares and I am delighted she continues to support the Company."

As a result of the acquisition Ms Polland has notified the Company that she is interested in a total of 4,758,834 shares, representing approximately 3.55 per cent. of the Company's issued shares.

Following the purchase of shares by Mr Smith, and the sale of shares by Mr Abony, the interest of the Directors in shares of the Company is as set out below:

Name

Interest in Shares

Options held (inc. unvested Options)

% interest in the Issued Shares

 

Lorne Abony1

24,496,870

12,131,548

18.27%

Stephen Dattels2

15,209,248

3,032,887

11.34%

Jim Mellon3

10,425,991

1,516,444

7.77%

Ian Burns4

1,374,024

NIL

1.02%

Bryan Smith

1,155,668

NIL

0.86%

1 Mr Abony's interest in shares is held by Abony Enterprises Limited Partnership, a limited partnership of which he is the majority legal owner.

2 Mr Dattels' interest in shares is held by Regent Mercantile Holdings Limited, a company owned by a trust under which Mr Dattels is a discretionary beneficiary. Mr Ian Burns is a director of Regent Mercantile Holdings Limited.

3 Mr Mellon's interest in shares is held by Galloway Limited, a company owned by a trust of which Mr James Mellon is a life tenant.

4 Mr Burns' interest in shares is held by Smoke Rise Holdings Limited, a company of which he is the sole shareholder.

For further information please visit www.fstfwd.co or contact:

James Biddle/ Michael Cornish (Nomad)

Beaumont Cornish LimitedTel: +44 207 628 3396

 

Peterhouse Corporate Finance Limited

Guy Miller/ Lucy Williams

Tel: +44 (0) 207 469 0930

Elysium Fund Management Limited

PO Box 650

1st Floor

Royal Chambers

St Peter Port

Guernsey

GY1 3JX

 

Tel: +44 1481 810 100

Fax: +44 1481 810 120

e-mail: elysium@elysiumfundman.com

CAUTIONARY STATEMENT

The AIM Market of London Stock Exchange plc does not accept responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of FastForward Innovations Limited. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. FastForward Innovations Limited assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBELFLQEFZBBZ
Date   Source Headline
25th Feb 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
18th Feb 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
11th Feb 20207:00 amRNSUpdated Key Information Document
31st Jan 20201:30 pmRNSInvestee Company Update: Portage Biotech Inc.
8th Jan 20207:00 amRNSDisposal of Interest in Cryptologic Corp
7th Jan 20207:00 amRNSBoard Appointment
3rd Jan 20201:15 pmRNSInvestee Company Update: Portage Biotech Inc.
11th Dec 20197:00 amRNSHalf-year Report
5th Dec 20192:45 pmRNSTR-1 Notification
19th Nov 20197:00 amRNSLorne Abony appointed as Chairman of EMMAC
16th Oct 20197:00 amRNSInvestee Company Update: EMMAC Life Sciences
15th Oct 20197:00 amRNSInvestee Company Update: Factom inc.
10th Oct 20199:25 amRNSResult of 2019 AGM
27th Sep 20194:31 pmRNSDirector Dealing in the Company
27th Sep 20197:00 amRNSInvestee Company Update : Fralis LLC (Leap Gaming)
26th Sep 201911:21 amRNSInvestee Company Update : Cryptologic Corp
16th Sep 201911:52 amRNSTR-1 Notification of major holdings
11th Sep 20198:00 amRNSResults for the year ended 31st March 2019
11th Sep 20198:00 amRNSNotice of 2019 Annual General Meeting
22nd Aug 201912:01 pmRNSDirectorate Change
19th Aug 20199:23 amRNSJuvenescence closes Series B funding
12th Aug 20193:02 pmRNSInvestee Company Update-Cryptologic issues loan
12th Aug 201910:11 amRNSPortage Trading Suspended
6th Aug 20194:42 pmRNSInvestee Company Update: Cryptologic Corp
30th Jul 201911:07 amRNSSAFE Agreement with Factom, Inc. Extended
25th Jul 20198:17 amRNSFactom Inc SAFE Agreement temporary extension
18th Jul 201911:20 amRNSInvestee Company Update: Regent Pacific on Yooya
16th Jul 20199:13 amRNSInvestee Company Update:EMMAC acquires Terre Verde
11th Jul 20193:00 pmRNSDisposal of interest in Intensity Therapeutics Inc
9th Jul 201910:51 amRNSInvestee Company Update: EMMAC enters new Market
26th Jun 20198:56 amRNSInvestee Company Update: Intensity Therapeutics
29th May 20193:43 pmRNSInvestee Company Update: Offer for Yooya
13th May 201910:21 amRNSDisposal of interest in Vemo Education Inc.
18th Apr 20197:00 amRNSInvestee Company Update: Intensity Therapeutics
4th Apr 20199:51 amRNSTR1 - Correction
3rd Apr 20194:00 pmRNSTR:1 Regent Mercantile Holdings Limited
20th Mar 201911:00 amRNSCompletion of £2 million investment in EMMAC
7th Mar 20194:03 pmRNS£2 million investment in EMMAC Life Sciences
15th Jan 20193:45 pmRNSJuvenescence Series B Funding
3rd Jan 201911:47 amRNSBoard Appointment
12th Dec 201812:52 pmRNSHalf-year Report
3rd Dec 20187:00 amRNSInvestee Company Update: Factom and Yooya
14th Nov 20181:31 pmRNSInvestee Company Update: Factom Inc
22nd Oct 201812:24 pmRNSIntensity Therapeutics Inc Update
12th Sep 20186:12 pmRNSResult of AGM
10th Sep 20189:16 amRNSHolding(s) in Company
22nd Aug 20188:08 amRNSDirector Dealing
3rd Aug 201812:48 pmRNSShareholder update
3rd Aug 20188:00 amRNSPlacing
1st Aug 201812:05 pmRNSResponse to Media Speculation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.